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Materials which undergo self-assembly to form supermolecular structures can provide 21 
alternative strategies to drug loading problems in controlled release application. RADA 16 is 22 
a simple and versatile self-assembling peptide with a designed structure formed of two 23 
distinct surfaces, one hydrophilic and one hydrophobic that are positioned such a well-24 
ordered fashion allowing precise assembly into a predetermined organization. $ ³VPDUW´25 
architecture in nanostructures can represent a good opportunity to use RADA16 as a carrier 26 
system for hydrophobic drugs solving problems of drugs delivery. In this work, we have 27 
investigated the diffusion properties of Pindolol, Quinine and Timolol Maleate from 28 
RADA16 in PBS and in BSS-PLUS at 37 °C. A sustained, controlled, reproducible and 29 
efficient drug release has been detected for all the systems, which has allow to understand the 30 
dependence of release kinetics on the physicochemical characteristics of RADA16 structural 31 
and chemical properties of the selected drugs and the nature of solvents used. For the analysis 32 
various physicochemical characterization techniques were used in order to investigate the 33 
state of the peptide before and after the drugs were added. Not only does RADA16 optimise 34 
drug performance, but it can also provide a solution for drug delivery issues associated with 35 
lipophilic drugs.  36 
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1. Introduction 37 
Hydrogels are cross-linked hydrophilic polymer networks that can absorb more than 100 38 
times their dry weight in water, giving them physical characteristics similar to soft tissue 39 
[Gibas et al., 2010]. Self-assembling peptide hydrogels are an important class of hydrogels, 40 
which are potentially excellent materials for various molecular controlled release applications 41 
[Nagai et al., 2006]. Self-assembly is a spontaneous process by which several individual 42 
molecules are associated into a coherent and organized structure under thermodynamic 43 
equilibrium conditions by non-covalent interaction, such as ionic and hydrogen bonding 44 
[Zhang et al., 1993; Jun et al., 2004; Zhaoyang et al. 2008]. In comparison with chemically 45 
synthesized polymer materials, self-assembling peptide hydrogels have numerous advantages, 46 
for example, (i) the peptides that construct the hydrogels can often be degraded in vivo, and 47 
the resulting products (amino acids) are nontoxic; (ii) the hydrogels are spontaneously formed 48 
without using harmful chemicals such as cross-linkers; (iii) the spontaneous process allows 49 
for an solution-gel transformation in vivo by injecting peptide solutions at specific locations, 50 
and it also enables a facile incorporation of cell-specific bioactive moieties into hydrogels; 51 
(iv) the peptide building blocks represent a variety of chemical groups that allow hydrogels to 52 
be easily modified with chemical and biological moieties; and (v) the hydrogel maintains a 53 
high water content, which may allow for the diffusion of a wide range of molecules [Zhang et 54 
al.,2002; Zhang, 2003; Huang et al., 2011]. Peptide hydrogels have been demonstrated to be 55 
useful as controlled release devices [Nagai et al., 2006; Koutsopoulos et al., 2008]. 56 
Depending on molecular design, many different hydrogels (e.g. P11-family [Aggeli et al., 57 
2003; Carrick et al., 2007], MAX8 [Altunbas et al.,2011], Fmoc-FF with KGM [Jayawarna et 58 
al., 2009], EAK16 [Keyes et al., 2004] and RADA16 [Gelain et al., 2010]) have been 59 
constructed.  For our study we have used RADA16 which has a high propensity to self-60 
assemble into hydrogels with nanofibre structures containing ׽99.5% w/v water ensuring the 61 
biodegradability [Arosio et al., 2012]5$'$NQRZQDV³PROHFXODU/HJR´ [Zhang, 2002], 62 
has two surfaces ± one hydrophilic composed of alternating arginine (positive charge) and 63 
aspartic acid (negative charge), and one hydrophobic surface enabling formation of supra-64 
PROHFXODU DVVHPEOLHV E\ D ³ORFN DQG ILW´ PRGHO >Nune et al., 2013]. Moreover, RADA16 65 
contains a regular repeat of alternating hydrophobic and hydrophilic amino acids [Yokoi et 66 
al., 2005] forming a hydrogel with a large surface to volume ratio [Zhang, 2003]. Alternation 67 
RIK\GURSKRELF DQGK\GURSKLOLF DPLQRDFLGV WHQGV WRSURPRWHȕ-strand secondary structure 68 
and two structural features that lead to stable nanofibre formation: (1) hypothesized hydrogen 69 
bonding between neighbouring peptide backbones, stabilizing a possible cross-ȕ VWUXFWXUDO70 
motif well-known to describe amyloid fibrils [Jonker et al.,2012; Eanes et al., 1968] and (2) 71 
separation between hydrophobic and hydrophilic faces that are believed to form the core and 72 
surface of nanofibres, respectively [Yokoi et al.,2005]. According to previous studies [Nagai 73 
et al., 2006; Koutsopoulous et al., 2008], RADA16 is an efficient delivery carrier but has not 74 
been used for hydrophobic drugs. Therefore, ZHK\SRWKHVL]HWKDWWKLV³VPDUW´DUFKLWHFWXUHLQ75 
nanostructure would allow loading hydrophobic drugs and permitting a sustained and 76 
controlled release providing solution for delivery problems. Therefore, we hypothesized that 77 
WKLV ³VPDUW´ DUFKLWHFWXUH PD\ HQFDSVXODWH VPDOO K\GURSKRELF PROHFXOHV EHWZHHQ SHSWLGH78 
chains, disrupting ȕ-VKHHW IRUPDWLRQ WR D PRUH Į-helix configuration but permitting a 79 
sustained and controlled release providing solutions for delivery problems. In order to 80 
investigate our hypothesis, we have explored the release profiles of Pindolol (P), Quinine (Q) 81 
and Timolol maleate (T) from RADA16 hydrogel. The drug release was investigated in PBS 82 
and BSS Plus solutions at 37 °C. The developed formulations were further characterized by 83 
atomic force microscopy (AFM), circular dichroism (CD) spectrometer and Fourier transform 84 
infrared spectroscopy (FT-IR). The molecules were chosen to have a range of partition 85 
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coefficients (LogP) and acid dissociations constants (pKa).  86 
 87 
2. Materials and Methods 88 
 89 
2.1. Chemicals and reagents 90 
The ac-(RADA)4-CONH2 peptide in 1 % solution was obtained from BD Biosciences 91 
(Bedford, MA).  Pindolol (Fig.1a; Table 1a LV D QRQVHOHFWLYH ȕ-blocker with partial ȕ-92 
adrenergic receptor agonist activity. Quinine (Fig.1b; Table 1b) is a natural white crystalline 93 
alkaloid having antipyretic, antimalarial, analgesic and anti-inflammatory properties. Timolol 94 
maleate salt (Fig.1c; Table 1c) is a non-selective beta-adrenergic receptor antagonist 95 
indicated for treating glaucoma, heart attacks and hypertension. All drugs were purchased 96 
from Sigma-Aldrich. Phosphate buffered saline (PBS) is an aqueous solution containing 97 
sodium chloride, sodium phosphate, and, in some formulations, potassium chloride and 98 
potassium phosphate. PBS solution was prepared using PBS buffer tablets (pH 7.4), and 99 
purchased from Sigma Aldrich. BSS-Plus is a sterile intraocular irrigating solution with pH 100 
7.4, which was purchased from Alcon ± UK. It is a complex solution with sugar and salts and 101 
it copies the physiological conditions of eyes providing an interesting study for T, which is 102 
used in glaucoma therapy. Furthermore BSS-Plus is used in this study to investigate a 103 
possible novel interaction between peptide and selected drugs due the nature of the different 104 
solvent. BSS-Plus is formed from sodium chloride 7.44 mg, potassium chloride 0.395 mg, 105 
dibasic sodium phosphate 0.433 mg, sodium bicarbonate 2.19 mg, hydrochloric acid and/or 106 
sodium hydroxide, calcium chloride dihydrate 3.85 mg, magnesium chloride hexahydrate 5 107 
mg, dextrose 23 mg, glutathione disulfide (oxidized glutathione), 4.6 mg in water for 108 
injection.  109 
 110 
2.2. Drug Release Experiments 111 
 112 
+\GURJHO IRUPDWLRQ RFFXUUHG E\ PL[LQJ  ȝ/ RI WKH >$F-(RADA)4-CONH2] peptide 113 
VROXWLRQ ZLWK  ȝ/ RI GUXJ DQG ZLWK  ȝO of PBS. The mixture was transferred into 114 
microcentrifuge tubes, and gelation occurred within 20 mLQ6XEVHTXHQWO\ȝ/RI release 115 
medium (PBS or BSS-Plus) was slowly added to each gel mixture. Experiments were 116 
performed in triplicates. The release experiments were performed at 37 °C, for a period of 7 117 
days, where the supernatant drugs concentration was measured at 15 min, 30 min, 1, 2, 3, 4, 118 
24, 48, 72 h and 7 days. To satisfy the perfect-sink conditions which allow for the 119 
determination of the diffusion parameters, the supernatant was replaced with fresh PBS or 120 
BSS Plus pre-equilibrated at 37 °C at each time point. The concentration of the drug 121 
molecules inside the hydrogel and in the supernatant was determined by UV-Vis using a 122 
Varian 50 bio UV-visible spectrophotometer at room temperature. The concentration of the 123 
drug molecules released from the hydrogel was determined using a calibration curve of the 124 
pure drug molecules in PBS and BSS-Plus solutions at the wavelength where showed the 125 
maximum absorbance (Table 1). During the course of the measurements the hydrogel volume 126 
did not change.  127 
 128 
2.3. Diffusivity determination from released drugs concentration 129 
 130 
For a hydrogel matrix that contains a molecularly dispersed diffusing agent, the apparent 131 
diffusion coefficient was calculated by using the 1-D unsteady-state form of )LFN¶V VHFRQG132 
law of diffusion for a plane film of thickness: 133 
 134 
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ఋ௖ఋ௧ ൌ ܦ ఋమ௖ఋ௫మ                                                     (Eq.1) 135 
 136 
where D is the diffusion coefficient of the active agent in the hydrogel and c is the 137 
concentration of the drug as a function of time (t) and position (x) [Frisch, 1970; Siepmann et 138 
al.,1998]. 139 
 140 
Diffusion is concentration independent and it occurs only in the positive x direction from the 141 
hydrogel to the sink. Assuming that (1) the rate at which the substance is transported to the 142 
surface is equal to the internal diffusion rate, (2) there are not solute-carrier interactions and 143 
(3) at time zero a contact between the hydrogel surface and the perfect sink is reached, Eq.(1) 144 
can be considered as [Korsmeyer et al., 1983; Ritger and Peppas, 1987; Siepmann and 145 
Peppas, 2001]: 146 
 147 ெ೟ெಮ ൌටସ஽௧గுమ                                                    (Eq.2) 148 
 149 
Mt and Mare the total mass of the diffusing compounds released after time t and infinite 150 
time, respectively.  151 
 152 
In order to calculate the diffusion coefficient (D0) as the drug concentration within the 153 
hydrogel approaches zero after a long diffusion time, Eq. (2) can be recast into: 154 ሺܯஶ െܯ௧ሻ ൌ   ቀ଼ெಮగమ ቁ െߠଶݐ                  (Eq.3) 155 ߠଶ ൌെ ஽బగమுమ                                                     (Eq.4) 156 
Furthermore, the diffusion coefficient was also calculated using the Stokes-Einstein equation 157 
[Vahdat and Sullivan, 2001], which calculates the free bulk diffusion coefficient as a function 158 
of the Boltzmann constant (kB), temperature (T), solvent dynamic YLVFRVLW\ ȝ DQG VROXWH159 
radius (rH). 160 
 161 ܦௌିா ൌ ௄ಳ்଺గఓ௥ಹ                                                 (Eq.5) 162 
 163 
kB is the Boltzmann Constant (1.3806503 x 10-23 m2 kg s-2 K-1ȉLVWKHDEVROXWHWHPSHUDWXUH164 
RIWKHPHGLXPLH.ȝLVWKHVROYHQWG\QDPLFYLVFRVLW\WDNHQDVF3DQGUH is 165 
the hydrodynamic radius which is different for each drug. 166 
 167 
It should be mentioned that due to the fact there exists an interaction between the solute and 168 
the nanofibres the calculated diffusivities are considered to be apparent diffusivities and 169 
allow for a comparison of the systems under study. 170 
 171 
2.4. Dissolution data analysis 172 
 173 
The dissolution kinetics was analysed by SigmaPlot 10.0 software (Systat Software 174 
Inc.,Chicago,IL) considering various mathematical models (Table 2) and determining the 175 
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amounts of drug released. 176 
 177 
2.5. Atomic force microscopy (AFM)  178 
After sonication of the ac-(RADA)4-CONH2 solution for 30 min, aliquots of 10 µl were 179 
UHPRYHGIURPWKHSHSWLGHVROXWLRQDQGGLOXWHGZLWKORIZDWHU0LOOLSRUH0FP180 
and left for 45 min in order to form fibres. One microliter sample was immediately deposited 181 
onto a freshly cleaved mica surface (1.5 cm x 1.5 cm; G250-2 Mica sheets 1" x 1" x 0.006"; 182 
Agar Scientific Ltd, Essex, UK) and left on the mica for 15 s, then rinsed with 100 µl of 183 
ZDWHU 0LOOLSRUH  0 FP DLU-dried, and images were acquired immediately. The 184 
images were obtained by scanning the mica surface in air under-ambient conditions using a 185 
Multimode 8 scanning probe microscope (Digital Instruments, Santa Barbara, CA, USA), 186 
operating using the new mode PeakForce QNM. The AFM measurements were obtained 187 
using ScanAsyst-air probes, for which the spring constant (0.58 N/m; nominal 0.4 N/m) and 188 
deflection sensitivity had been calibrated, but not the tip radius (the nominal value used was 2 189 
nm). AFM images were collected from two different freshly prepared samples and at random 190 
spot surface sampling (at least seven areas per sample). 191 
 192 
2.6. Circular dichroism (CD)  193 
The far-UV CD spectra of the ac-(RADA)4-CONH2 with P,T and Q were recorded between 194 
180 and 260 nm on a Chirascan CD spectrometer (applied Photophysics, UK). 100 µL of the 195 
peptide solution were added in a 0.1 mm path-length quartz cuvette, and the measurements 196 
were carried out at 20 °C (1 nm bandwidth resolution, and current time-per-point of 3 s). 197 
Typically, three scans were recorded, and baseline and PBS spectra were subtracted from 198 
each spectrum. Data were processed using Applied Photophysics chirascan Viewer at room 199 
WHPSHUDWXUHDQGQHXWUDOS+ZKLFKLVLQDFFRUGDQFHZLWKOLWHUDWXUHWKDWFRQILUPVWKHW\SLFDOȕ-200 
sheet spectra [Yokoi et al., 2005]. 201 
 202 
2.7. Fourier-transform infrared spectroscopy (FT-IR)   203 
FT-IR spectra were recorder on a Nicolet iS10 (ThermoScientific) Smart iTR 204 
spectrophotometer. The spectra were taken in the region 4000 and 500 cmí1 over 128 scans at 205 
a resolution of 4 cmí1 and an interval of 1 cmí1. Here we show only the region 1740 and 206 
1560 cmí1, since that region shows WKHȕ-sheet structure, which was used to validate the CD 207 
results. Spectra of the ac-(RADA)4-CONH2 in PBS with and without drugs were recorded, 208 
and each spectrum was background subtracted. 209 
 210 
3. Results and Discussion 211 
 212 
3.1. AFM 213 
7RJDLQLQVLJKWLQWRWKHK\GURJHO¶VPRUSKRORJ\$)0ZDVXVHG providing clear support for 214 
self-assembly of peptides. Since RADA 16 is a peptide hydrogel with a secondary structure 215 
WKDWLVODUJHO\FRPSULVHGRIȕ-sheet, resulting in fibrils with diameters on the nanoscale, it can 216 
be defined as amyloid hydrogel [Knowles et al., 2010]. Confirming what the literature 217 
asserts, RADA 16 combined with the drug selected may form nanofibre that can be affected 218 
by changes depending on the drugs structure encapsulated into the hydrogel [Mains et al., 219 
2013]. The images of drug loaded hydrogel (Fig. 2a-c) show that the addition of the chosen 220 
drug molecules has no distinct chaotropic or kosmotropic effect on the self-assembly of the 221 
functionalized peptides. The images detected from the combination between RADA16 and 222 
drugs, reveal morphological differences of nanostructures formed. In particular, two 223 
remarkably different morphologies of nanofibres were obtained from the interaction between 224 
RADA with P and Q (Fig.2a-b) and RADA with T (Fig.2c). P and Q loaded hydrogels show 225 
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no amyloid fibril formation producing a high density of nanofibres randomly distributed on 226 
the mica surface. The nanostructures consist of cross-linked network structures including 227 
elongated, thickened and twisted fibres. A large number of crosslinking points suggest a self-228 
assembled into a denser network.  T loaded hydrogel produces amyloid fibres in accordance 229 
with literature [Mains et al., 2013]. The formation of these fibres can be a potential 230 
consequence of a major PL[HG FRQWHQW EHWZHHQ Į-KHOL[ DQG ȕ-sheet [VandenAkker et al., 231 
2011] compared to the P and Q loaded RADA 16.  232 
 233 
To quantitatively analyse the data, a large amount of the images has been examined in order 234 
to find the surface coverage of nanofibres, clusters and branches and further calculate the 235 
dimensions of nanofibres, which are reported in Table 3. The diameter of nanofibres for P 236 
and Q is the same confirming the similar interaction showed in Fig.2a-b between RADA 16 237 
and drug loaded. The values carried out for P and Q show fibrous structures having width 238 
between a range of 6-8 nm, which is in excellent agreement with the molecular dimension of 239 
WKHȕ-sheet peptide [Zhao et al., 2009]. In direct contrast, T has larger fibres justifying the 240 
different arrangement indicated in Fig.2c. These results, despite the different interactions with 241 
the drugs selected, define RADA 16 as a unique candidate to easily incorporate hydrophobic 242 
drugs into the gel matrix due the capacity to keep an unchanged morphology of nanostructure 243 
after drugs encapsulation. 244 
 245 
3.2. CD and FT-IR 246 
During the drugs residence in the peptide solution, during self-assembly and nanofibre 247 
formation or during the release process, denaturation of hydrogel and destructive interaction 248 
between drugs and RADA16 could occur. To better understand the state of the peptides under 249 
different conditions, we have investigated their secondary structure using FT-IR and CD. 250 
7\SLFDO ȕ-sheet spectra were observed at each point in time, indicating the molecular 251 
structure and the integrity of the peptides before and after the drug incorporation [Yokoi et 252 
al., 2005; Zhang et al.1995].  Fig.3 shows the CD spectra of RADA16 and drug loaded 253 
systems. Measurements were carried out in the visible and ultra-violet region of the electro-254 
magnetic spectrum monitor electronic transitions. For all experiments, the analyses show a 255 
negative maximum at 220-221 nm and a positive maximum at 196 nm in concordance with 256 
literature values [Nagai et al., 2012]. Moreover, the FKDUDFWHULVWLFSHDNV WRGHVFULEHĮ-helix 257 
approximately at 222 nm [Correa and Ramos, 2009] DQG ȕ-sheet at 216 nm [Correa and 258 
Ramos, 2009] were analysed (Table 4). All CD spectra DUH FRQVLVWHQW ZLWK ȕ-sheet rich 259 
structures even after addition of drugs. The results suggest that at the molecular scale the 260 
LQGLYLGXDOSHSWLGHVGLGQRWEUHDNLQWRPRQRPHUVEXWIRUPHGVWDEOHȕ-sheets and were packed 261 
together. The small differences in the ellipticity intensities that are observed in the CD 262 
spectra, propose that the elliptically polarized light when passed through the circular dichroic 263 
sample shows a different magnitude due to the characteristic absorbance of the samples 264 
selected [Uversky and Permyakov, 2007]. Furthermore, CD analysis reveals structural 265 
information which corroborates with the AFM images (Fig.2). The spectra for the P and Q 266 
SHUIHFWO\IROORZWKHH[WHQGHGȕ-structure of the RADA 16. T, despite maintains a consistent 267 
secondary structure, shows a slightly different behaviour than the spectrum for RADA 16 268 
without drug loaded. T spectrum shows a mixed content between Į-KHOL[ DQG ȕ-sheet 269 
[VandenAkker et al., 2011] compared to the other drug loaded systems (Table 4) permitting a 270 
completely different folding of hydrogel which is supported by the AFM image of observed 271 
fibres for the T system. 272 
 273 
To validate the CD data further FT-IR spectroscopy has been usedVLQFHWKHIRUPDWLRQRIȕ-274 
sheet-like structures can be monitored through the absorption of the amide group in FT-IR 275 
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spectroscopy. The FT-IR spectra (Fig.4), dashed line shows the signal for RADA16 without 276 
drug signal, and the continuous lines display the signal detected from interaction between 277 
drugs and peptide. In all experiments, before and after added drugs, a peak around 1616 cm-1 278 
was detected. For conventional self-assembling peptides, a peak around 1615 cm-1 indicates 279 
WKH SUHVHQFH RI DJJUHJDWHG ȕ-sheets [Yokoi, 2005], [Zhang et al., 1995@ ,Q WKH ȕ-pleated 280 
sheet, the sheet-like structure is created by a series of hydrogen bonds between residues in 281 
different polypeptide chains or between residues in different sections of a folded polypeptide 282 
[Kumar et al., 2011]. Amide I bands at 1619 and 1616 cmí1 is the most structurally sensitive 283 
IR band; it mainly associated with the C=O stretching vibration and is directly related to the 284 
backbone conformation [Krimm and Bandekar, 1986]. The band at 1618 cm-1 is consistent 285 
with an antiparallel conformation, which shows that the fibres run in opposite directions 286 
[Kumar et al., 2011]. The band Amide II absorption peaks at 1526 and 1543 cmí1 results 287 
from the N-H bending vibration and from the C-N stretching vibration [Jackson and Mantsch, 288 
1991]. In all spectra detected (Fig.4), the position of the peaks between spectra of RADA and 289 
RADA with drugs remains constant confirming the results obtained with CD. However, 290 
taking into consideration AFM results obtained, P and Q non-loaded amyloid fibres show 291 
similar amide I profiles to T loaded amyloid fibres but with slight differences in peak 292 
intensities. One evident discrepancy is visible in Fig.4 where the peak intensity of RADA 293 
with T, DVVRFLDWHGZLWKȕ-sheet contribution, overhangs the peak of RADA 16 without drug 294 
loaded. Furthermore, in accordance with CD results, T amyloid fibre spectrum shows a 295 
different proportion of Į-helix at 1637 cm-1 [Petty and Decatur, 2005] respect P and Q 296 
spectra. 297 
 298 
3.3. Drug release 299 
In order to further explore the potential of self-assembling peptide hydrogels as drug delivery 300 
system for hydrophobic drug molecules by proving a solution for delivery problems, it is 301 
imperative that the physicochemical characteristics of RADA16, the structural and the 302 
chemical properties of the drugs are taken into consideration. 303 
The release of the drugs from the peptide nanofibre hydrogel is illustrated in Fig.5, as a plot 304 
of mass released fraction (Mt0 DV D IXQFWLRQ RI WLPH W The model was developed 305 
assuming diffusion of small molecules, infinite dilution of the diffusant, and that the diffusion 306 
of the molecules through the hydrogel depends solely on Brownian motion [Koutsopoulous et 307 
al., 2008]. Racking one-dimensional solute release from a thin polymer slab of thickness 308 
where the initially drug concentration is maintained constant, a perfect sink condition is 309 
referred [Ritger and Peppas, 1986] providing a controlled release. These conditions permit to 310 
ignore the transport within the sink condition when calculating the overall release rate of the 311 
drug from the hydrogel [Nagai et al., 2005]. In the pharmaceutical field, several equations 312 
have been developed to model diffusional release from polymer [Rosema and Cardarelli, 313 
1980] [Peppas, 1984], but the most acceptable expression to simplify the analysis of 314 
controlled release from various classical geometric shapes for non-swellable polymeric 315 
delivery systems was proposed by Peppas [Peppas, 1985] . Eq.4 is commonly used to 316 
determine apparent diffusion coefficients even when these conditions do not apply. The 317 
reason for doing this is that it facilitates the discussion of systems where there is no other 318 
easily transferable method for determining the diffusivity [Rosenbaum, 2011].  319 
Furthermore, plotting the release data as function of the square root of time, Fig.6 shows a 320 
biphasic diffusion mechanism. The initial linear part of each plot indicates diffusion 321 
controlled release of the drugs from RADA16 and the diffusion coefficients were calculated 322 
following Eq.3 DFFRUGLQJZLWK)LFN¶VODZ$GHYLDWLRQIURPWKHVWUDLJht line at longer time is 323 
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evident after 4 hours (t0.5/s0.5: 120). This deviation from Fick behaviour may occur due the 324 
presence of hydrogel pores with small size and/or diffusion hindrance caused by specific 325 
interactions between diffusing drug molecules and peptide nanofibre of the hydrogel. In order 326 
to describe the non-linear regression model, SigmaPlot software was used to calculate the 327 
model parameters and the determination coefficients (R2). There are several mathematical 328 
models to describe the kinetic profile of the considered drugs from the hydrogel formulation 329 
and to provide a good understanding of the drug dissolution [Costa and Lobo, 2000] 330 
[Kitazawa et al., 1977]. In this study three models were examined, using the equations 331 
presented in Table 2. The parameters calculated by these models and the determination 332 
coefficients (R2) obtained are summarized in Table 5. The fit of each model was predicted 333 
based on some estimation: a) the dissolution profile described is a drug diffusion model for 334 
the case of diffusion of an initially uniformly distributed drug thought a polymeric matrix 335 
[Korsmeyer et al., 1983][ Siepmann and Peppas, 2001]; b) the dissolution exponent (n) 336 
GHWHUPLQHV WKH GRPLQDQW UHOHDVH PHFKDQLVP DQG WKXV LI Q   D )LFNLDQ GLIIXVLRQ LV337 
GHWHFWHGLIQDQRQ-)LFNLDQGLIIXVLRQLVLGHQWLILHGDQGLIQD]HURRUGHULV338 
shown; c) when drug release is proportional to that remaining in the dosage form, dissolution 339 
can be described by first order release kinetics [Gibaldi and  Feldman, 1967] [ Wagner, 340 
1969]; d) the Higuchi equation describes also the cumulative amount of released drug per unit 341 
area is proportional to the square root of time [Higuchi, 1963]. As it can be seen in Table 5, 342 
R2 have similar value in more than one kinetic model and the dissolution rate constants reveal 343 
that Korsemeyer-Peppas is the predominant mechanism and fits the dissolution profiles. 344 
Following the literature [Boyapally et al., 2010], the goodness of fit for all models was based 345 
on comparisons of the higher R2, smaller standard error of model parameters and smaller 346 
residual mean square for each model [Yuksel, 2000]. 347 
Fig.5 also shows the controlled release for all drug analysed in PBS and in BSS-Plus. Based 348 
on the release kinetics of the diffusing compounds we are able to categorize the drugs into: 349 
faster release drugs (T and P) and slower released drug (Q). Some of the release is sustained 350 
and a few faster because the formulation was not optimised showing a burst release and also 351 
it must be considered that the drug was not fully encapsulated in the hydrogels remaining on 352 
the surface.  353 
A summary of the data analysis for the drugs released from RADA16 is presented in Table 6. 354 
The results show that the Stokes-Einstein equation (DS-E: 3.33 x 10-10 for P; 2.82 x 10-10 for 355 
T; 4.71 x 10-11 for Q) overestimates the diffusivity of the drugs in solution. The reason for 356 
this discrepancy between the Stokes-Einstein diffusion coefficient and those determined by 357 
Eq.5 (D: 0.12 ± 0.03 x10-10 for P; 0.16 ± 0.04 x10-10 for T; 0.03 ± 0.005 x10-11 for Q) is 358 
probably because in these experiments we used microliter drugs concentration. Hence, 359 
molecular crowding may have affected protein diffusion by slowing the molecular motion 360 
[Rosenbaum, 2011]. T and P present similar diffusivity values, while Q shows a considerably 361 
smaller value indicating an interaction between Q and the peptide fibres. 362 
 363 
Fig.5a. shows the controlled release in PBS. The release profile shows the concentration of T 364 
in the supernatant increases quickly, more than 50 % of the loaded amount is released from 365 
the peptide scaffold in the first 1 h; T is released completely after 24 hours. Q was the slowest 366 
drug to be released in accordance with theoretical values and the initial hypothesis. P release 367 
reflects the T diffusion despite the longer time that it takes to leave the vehicle. P and T 368 
belong to the same pharmaceutical class of drugs, which means the pharmacophore is the 369 
same but with some structural differences, which can justified the delay in terms of delivery. 370 
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T in its structure presents a [1,2,5] thiadiazole group (Fig.1d) and P presents an indolic group 371 
(Fig.1b). Both rings are aromatics but according to the value of Bird structural index of 372 
aromaticity they have different values. The [1,2,5] thiadiazole has I=104 [Katritzky et al., 373 
2010] and the P has a value of I=146 [Estrada, 2006]. These values describe a higher 374 
aromaticity character for P. Based on the high specific bindings between aromatic groups and 375 
matrix of RADA16; it is hypothesized that an aromatic ring could be responsible of 376 
prolonged release [Choi et al., 2008]. The same explanation can be used to rationalize the Q 377 
release. The drug contains a quinoline ring (Fig.1d) which has I=134 [Estrada, 2006] proving 378 
that quinoline ring is more aromatic than [1,2,5] thiadiazole group; so Q is slower than T. 379 
However, the difference of Bird index between P (I = 146) and Q (I = 134) suggests that P 380 
should be the slowest on lipophilic drug group; but Q has a major steric hindrance with 7 381 
members ring (Fig.1d) which can reduce the diffusion capacity [Perale et al., 2012]. 382 
Furthermore it is likely to rationalize the order of release considering the pKa values of the 383 
drug selected (Table 1) and converting them into isoelectric points (pI). The pI values are 9.2 384 
for P and T and 8.7 for Q. The pI of Q is closer to the pH value of the environment (7.4); this 385 
condition ensures a strongly interaction between Q and RADA16 peptide nanofibres [Nagai 386 
et al., 2006]. 387 
 388 
Data show that all drugs demonstrated a controlled release and their accumulated drug 389 
released were 100 % (P, T) and 20 % (Q). Despite Q is not totally out from the delivery 390 
system, the experiment was stopped after 7 days since was not significant differences 391 
between concentration released after 3 days and after 7 days. In BSS-PLUS (Fig.5b), the 392 
sequence of release is the same shown in PBS. BSS-PLUS keeps the same pH value of PBS 393 
but the composition is not only saline; here we also have dextrose. The presence of sugar 394 
theoretically could change the conditions of interaction between drugs and RADA16; 395 
however the present data show that it did not happen for the specific hydrogel. BSS-PLUS is 396 
a sterile intraocular irrigating solution and it copies the physiological conditions of eyes. This 397 
characteristic can be interesting for the study of T, which is frequently used in glaucoma 398 
therapy. In BSS-Plus T release from RADA16 is constant and sustained although after 7 days 399 
not all the drug is carried out from the hydrogel.  400 
 401 
 402 
4. Conclusions 403 
In this work, we investigate the possibility of using a hydrogel consisting of self-assembling 404 
peptides as a carrier for controlled drug release of lipophilic drugs. We screened P, T and Q 405 
functionalized with RADA16 (Ac-(RADA)4-CONH2) in two different solvents (PBS and 406 
BSS-PLUS). By using AFM we have demonstrated that the addition of functional drugs motif 407 
sequences has no distinct impediment on the self-assembly of the functionalized peptides 408 
despite the physicochemical characteristics of the drugs chosen can modify the morphology 409 
of the nanostructures. &' DQG )7,5 GHPRQVWUDWHG WKDW 5$'$  DGRSWV VWDEOH ȕ-sheet 410 
structures and self-assembles also after addition of lipophilic drugs. We have shown that the 411 
release rate can be mainly controlled. Our data show that the release kinetics of the drugs 412 
analysed depends on their structure, on their chemical properties (e.g. LogP, pKa, pI, 413 
presence of aromatic rings, steric hindrance) and on the solvent chosen to study the release 414 
(e.g. PBS, BSS Plus). A sustained, controlled and efficient drug release has been achieved for 415 
lipophilic drugs from RADA16. Furthermore, the molecules with the same parameters (P and 416 
T) present similar behaviour in terms of drug release. These results indicate RADA16 as a 417 
³VPDUW YHKLFOH´ WR SURYLGH VROXWLRQV IRU UHOHDVH problems associated with lipophilic drugs. 418 
The present study holds importance in the context of new drug delivery formulations, in order 419 
to optimize drugs performances.  420 
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Figures legend: 572 
 573 
Fig.1. Chemical structures of the compounds used. a) Pindolol (P), b) Quinine (Q), and c) 574 
Timolol maleate (T). 575 
 576 
Fig.2. AFM images obtained from peptide RADA16 networks at scale 3.5 µm x 3.5 µm. a) 577 
RADA16 with P, b) RADA16 with Q, c) RADA16 with T, d) only RADA16 with an 578 
additional image at 250nm of scale bar. 579 
 580 
Fig.3. CD spectra of RADA16 with and without incorporated P, Q and T. RADA16 peptide 581 
KDGDW\SLFDOȕ-sheet structure. When drugs were incorporated with RADA16, there was not 582 
DQ\FKDQJHLQȕ-sheet structure. 583 
Fig.4. FT-IR spectra of RADA 16 with and without incorporated P, Q and T. The dashed line 584 
shows the signal for RADA16 without drug signal; the continuous lines display the signal for 585 
interaction between RADA16 and drugs. 586 
 587 
Fig.5. Cumulative release of P, Q and T. a) in PBS and b) in BSS-Plus. 588 
 589 
Fig.6. Linear fit obtained from drugs release of P, Q and T. a) PBS and b) BSS-Plus. 590 
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Table 1. List of drugs used in this work with their physicochemical properties. 614 
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Table 2. Applied dissolution models. 618 
Model Equation 
First order ܯ௧ ൌ ܯ଴݁ି௞௧ 
Higuchi ܯ௅ǡ௧ ൌ ݇ு ?ݐ 
Korsmeyer-Peppas ܨ ൌ ݇௣ݐ௡ 
F, amount of drug dissolved in time t; k and kp dissolution rate constants; n dissolution 619 
exponent.  620 
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Table 3. Values of dimension of nanofibres (d) and values of surface roughness (Ra) 621 
obtained from AFM analysis. 622 
 623 
Sample d / nm Ra / nm 
RADA 12.24 ± 1.09 0.53 ± 0.23 
P 7.76 ± 0.7 0.38 ± 0.10 
Q 7.57 ± 0.68 0.41 ± 0.16 
T 10.62 ± 0.74 0.46 ± 0.22 
  624 
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Table 5. Dissolution rate constants and determination coefficients of drug released from 628 
hydrogel formulations.  629 
 630 
Model  Pindolol Quinine Timolol 
First order k 2.1x10-2±6.3x10-3 5.4x10-3± 4.0x10-4 3.7x10-3± 2.4x10-4 
R2 0.9748 0.9821 0.9783 
Higuchi kH 7.048 ± 0.441 4.387 ± 0.354 2.837 ± 0.197 
R2 0.9865 0.9880 0.9745 
Peppas kp 6.698 ± 0.074 2.985 ± 0.033 4.394 ± 0.087 
R2 0.9983 0.9904 0.9951 
  631 
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Table 6. Diffusion parameters and calculated values for the compounds released from 632 
RADA16. 633 
 634 
 P T Q 
Volume / l 0.2 ± 0.01 0.2 ± 0.01 0.2 ± 0.01 
H / m 4.2 ± 0.04 x 10-3 4.2 ± 0.04 x 10-3 4.2 ± 0.04 x 10-3 
rh / m 6.8 x10-9 80 x 10-9 48 x 10-9 
D / m2 s-1 0.12 ± 0.03 x 10-10 0.16 ± 0.04 x 10-10 0.03 ± 0.005 x 10-11 
D0 / m2 s-1 0.05 ± 0.02 x 10-10 0.07 ± 0.02 x 10-10 0.004 ± 0.0001 x 10-11 
DS-E / m2 s-1 3.33 x 10-10 2.82 x 10-10 4,71 x 10-11 
Ǻ 0.07 0.09 0.05 
J / µg m-2 s-1 1.7 x 10-8 1.87 x 10-8 2.38 x 10-10 
 635 
 636 
